Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former FDA ODE II Director Meyer Building New Regulatory Sciences Center at UVA

This article was originally published in RPM Report

Executive Summary

Bob Meyer, a veteran of both sides of the FDA drug regulatory process from top-level positions in FDA’s drug review office and the Merck regulatory strategy and policy group, is trying to create a new regulatory science center at the University of Virginia that could add to FDA’s close-by academic support resources.

You may also be interested in...



Good Neighbors Make Good Regulatory Science Centers, FDA Decides

Georgetown, Maryland gain CERSI grants in part because of their proximity to agency staff.

Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?

FDA's drug review managers and staff are showing signs of wear and tear from the tough political climate for the agency. Some key staff have departed. Merck took advantage of the turmoil to get a manager with knowledge of the endocrine area, where the taranabant NDA will be filed.

FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus

CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel